Paraquat Settlement Amount Estimates

The table below shows the payout ranges legal analysts most often discuss, organized by the case profile each range tends to reflect. Read it as a map, not a price list: these figures come from comparable toxic-tort settlements and from attorneys watching the litigation, not from a single confirmed, public paraquat settlement schedule. The biggest variables are the strength of an individual case and, as of mid-2026, how the Supreme Court’s Durnell ruling ends up affecting the legal theory behind these claims — see the dedicated section below.

No global, itemized paraquat settlement schedule has been made public, and cases resolved so far — including a 2021 batch settlement and the January 2026 Philadelphia bellwether — were confidential. So there is still no verified per-person figure. Treat every number here as an estimate that may shift, especially given the Supreme Court development discussed below.

Quick Answers to the Top Questions

How much is a paraquat settlement per person?

Analyst estimates commonly cluster around $100,000–$150,000 on average, with a broader projected band of roughly $20,000 to $1,000,000+. A few plaintiff firms now float higher averages for the strongest cases, but nothing is guaranteed, and a single case’s value depends on the factors below. See what determines your payout.

Who qualifies?

Generally, people exposed to paraquat — by mixing, loading, spraying, or working and living near where it was applied — who were later diagnosed with Parkinson’s disease. Families can sometimes file on behalf of a loved one. See who qualifies.

Is there a settlement yet?

Not one finalized, public, court-approved global deal. A settlement framework has been rolling out since August 2025, many plaintiffs have accepted individual offers, a court-supervised settlement fund was authorized in March 2026 — but a large number of plaintiffs have opted out, and the June 2026 Supreme Court ruling has added a new layer of uncertainty. See the 2026 update.

How long until payouts?

There is no single firm date. Plaintiffs who accepted settlement offers are moving through claims processing now; payments in mass torts generally take months to a couple of years from acceptance. See the timeline.

Is it taxable?

The compensatory portion for a physical sickness like Parkinson’s is generally tax-free; punitive damages and interest are taxable. See the tax section and speak with a tax professional.

Is There a Paraquat Settlement Yet? (2026 Update)

Status as of mid-August 2026 — verify current details, because this litigation is moving fast.

The federal cases are consolidated in MDL No. 3004, In re: Paraquat Products Liability Litigation, before Chief Judge Nancy J. Rosenstengel in the U.S. District Court for the Southern District of Illinois. As of mid-2026, the docket held roughly 6,650–6,700 pending cases, with more in state courts. The primary defendants are Syngenta (the current manufacturer) and Chevron (which exclusively distributed paraquat in the U.S. from the mid-1960s until 1986 — see the box below). This is a multidistrict litigation, not a class action, so each case keeps its own individual value rather than splitting a shared award.

• August 2025A settlement framework was signed to resolve a large share of the MDL. Plaintiffs began being sent individual offers.
• January 27, 2026The first paraquat case set for trial — a Philadelphia state-court claim brought by a retired landscaper — settled confidentially the night before opening statements. It’s part of a broader pattern of the defense settling on the courthouse steps rather than letting a jury hear the evidence.
• January 2026The EPA announced it would review paraquat’s safety, separate from the litigation.
• March 2026The court authorized a qualified settlement fund (QSF) to help administer payouts, and a scheduled trial was canceled in light of the pending settlement.
• Spring 2026Syngenta announced it would wind down paraquat production. Read this carefully: the company has stated the move was made “solely for commercial reasons,” not as an admission that paraquat causes Parkinson’s — Syngenta continues to deny the link entirely. Treat the production wind-down as a business and litigation-risk decision, not medical evidence.
• May 26, 2026Vermont became the first U.S. state to ban paraquat, when Gov. Phil Scott signed H.739. The ban on sale and use takes effect November 1, 2026, with narrow, time-limited exemptions for certain orchard and berry crops through 2030. A similar bill has since advanced through a Pennsylvania House committee.
• June 12, 2026Judge Rosenstengel ordered any plaintiff who has not joined the settlement — including those who opted out or remain undecided — to meet with court-appointed Special Master Randi Ellis within 30 days. Opt-out plaintiffs also face depositions and limited third-party discovery so the court can confirm they understand what they’re walking away from.
• June 25, 2026The U.S. Supreme Court decided Monsanto Co. v. Durnell — a Roundup case, but one built on the identical legal theory paraquat claims use. See the dedicated section just below; this is arguably the single biggest development of the year for this litigation.
• July 2026A batch of roughly 30 cases was dismissed from the MDL for failing to comply with prior case-management orders — a housekeeping matter, not a sign the wider litigation is collapsing. The court also flagged unusually high opt-out rates among clients of a few specific law firms for extra review.
• August 11, 2026California’s Department of Pesticide Regulation confirmed that every paraquat manufacturer had voluntarily canceled its California product registration, phasing the herbicide out of the state. This stemmed from a separate DPR safety reevaluation (flagging possible thyroid and birth-defect concerns) rather than from the Parkinson’s litigation directly — companies chose to exit rather than submit the additional safety data DPR required.

The takeaway: a large amount of money has already moved through individual settlement offers, but this is not one tidy, finalized global deal, and the legal ground shifted meaningfully in June 2026. Anyone telling you a specific, guaranteed amount before you’ve had your own case reviewed is getting ahead of the facts.

The Supreme Court’s Durnell Ruling — Why It Matters Here

On June 25, 2026, the Supreme Court ruled 7–2 in Monsanto Co. v. Durnell that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts — that is, blocks — state-law “failure to warn” claims when the EPA has not required the warning being sought. The case was about Roundup and cancer warnings, not paraquat. But paraquat’s core legal theory is built the same way: plaintiffs argue Syngenta and Chevron should have warned about Parkinson’s risk even though the EPA has never required a Parkinson’s-specific warning on the label.

Because the legal architecture is essentially identical, both sides in the paraquat MDL have told the court the Durnell decision could shape whether the paraquat failure-to-warn claims survive. Syngenta had already raised this exact preemption argument in paraquat settlement negotiations months before the Supreme Court ruled. A few things are worth understanding if this affects you:

• It mainly threatens “failure to warn” claims. Other legal theories used in paraquat lawsuits — including design defect, negligence, fraud or concealment, and breach of warranty — are not automatically wiped out by Durnell, though how strongly they hold up case by case is still being worked out.
• Plaintiffs who already accepted a settlement offer are on a different track than those who opted out or haven’t filed yet. If you’ve accepted an offer, the ruling is unlikely to unwind that deal.
• Opt-out and future claimants face more uncertainty. If the preemption argument is applied broadly in the paraquat MDL, it could reduce leverage in negotiations or narrow which claims can proceed to trial.
• This is still developing. As of mid-August 2026, courts had not yet issued a definitive ruling on exactly how far Durnell reaches into the paraquat MDL specifically. This is exactly the kind of fast-moving legal question where a case-specific conversation with a paraquat attorney matters more than a general estimate.

What Determines Your Payout?

If a settlement is reached, individual amounts will not be uniform. In mass torts, claims are typically scored against a set of factors, and stronger evidence with a more severe diagnosis anchors the higher estimates. The main considerations:

For context, analysts often benchmark paraquat estimates against the Roundup litigation, where Bayer has paid out well over $10 billion combined to resolve a very large number of weed-killer cancer claims. That comparison is one reason the $100,000–$150,000 average circulates — but it is a projection, the two products and their science are not identical, and the post-Durnell legal landscape may push both litigations in new directions.

Who Qualifies for the Paraquat Lawsuit?

Eligibility generally turns on two things together: documented exposure to paraquat and a confirmed diagnosis of Parkinson’s disease. Exposure is not limited to the person holding the sprayer — people who mixed or loaded the chemical, worked in or near treated fields, or lived close to where it was applied may also have a claim. The table below outlines the most common groups.

If a loved one passed away from complications of Parkinson’s after paraquat exposure, surviving family members may be able to bring a claim. Those situations follow separate rules — our overview of wrongful death claims explains how that path differs. An attorney is the right person to confirm whether a specific situation qualifies.

How Do You Prove Exposure From Years Ago?

A common worry: “How do I prove I was around this chemical 15 or 20 years ago?” Because paraquat is a Restricted Use Pesticide (RUP), the EPA requires that only certified applicators buy and use it — and that creates a paper trail. Useful sources of proof include:

• RUP purchase and usage logs that certified applicators and farms are required to keep.
• Commercial or private applicator licenses issued by a state department of agriculture.
• Employment records showing a role that involved mixing, loading, or spraying.
• Farm or supplier purchase records, including receipts from paraquat distributors.
• Co-worker or family testimony describing the work and how often paraquat was handled.

On the medical side, attorneys generally look for a diagnosis of idiopathic Parkinson’s disease — meaning a physician has not identified a genetic or other clear alternative cause. That “differential diagnosis” step, ruling out other explanations, is part of why solid medical records matter as much as exposure records.

What Symptoms and Conditions Qualify?

The qualifying condition is Parkinson’s disease — and, in some cases, related parkinsonism diagnosed by a physician. Parkinson’s is a progressive neurodegenerative disorder, and the symptoms most often associated with a diagnosis include:

• Tremor — shaking that frequently begins in a hand or fingers, often when the limb is at rest.
• Bradykinesia — a general slowing of movement that can make everyday tasks take much longer.
• Rigidity — muscle stiffness that may be painful and limit range of motion.
• Postural instability — impaired balance and coordination that raises the risk of falls.

Other changes — a softening voice, reduced facial expression, smaller handwriting, or a diminished sense of smell — can accompany the disease. For a claim, the essential combination is a physician-confirmed diagnosis (ideally idiopathic, with other causes ruled out) paired with a documented history of paraquat exposure. A diagnosis alone, or exposure alone, is generally not enough; the two need to be connected.

What Is Paraquat — and the Parkinson’s Link?

Paraquat dichloride is a fast-acting herbicide used widely in U.S. agriculture, often sold as Gramoxone and frequently applied where weeds have grown resistant to glyphosate. It is highly toxic; the EPA classifies every paraquat product registered in the country as a Restricted Use Pesticide, meaning it can be handled only by trained, certified applicators, with no residential uses — see the EPA’s paraquat dichloride page. It has been banned in dozens of countries — including the European Union and China — and, as of 2026, Vermont became the first U.S. state to ban it, with California effectively phasing it out through canceled registrations. It remains legal for licensed use elsewhere in the United States under restricted-use rules, though the EPA announced in January 2026 that it would review the chemical’s safety.

Exposure typically happens through skin contact, inhaling spray or mist, or accidental ingestion during mixing, loading, application, or cleanup, and through drift onto nearby people. The concern driving the lawsuits is the connection to Parkinson’s. Research funded by the National Institute of Environmental Health Sciences reported that people who occupationally used paraquat (or the pesticide rotenone) developed Parkinson’s disease notably more often than non-users, and a long-running body of research has identified paraquat among the pesticides linked to the disease’s onset and progression. The NIEHS overview of the environmental links to Parkinson’s disease summarizes this work. The claims center not on the chemical’s existence but on an alleged failure to adequately warn users of that risk — the same theory now under legal pressure after the Durnell ruling described above.

Paraquat is one of several toxic-exposure fights moving through the courts, and it isn’t the only pesticide facing this kind of claim — a smaller wave of chlorpyrifos-related Parkinson’s suits has also begun. If you are researching how these cases work, our guides to the Camp Lejeune toxic-water litigation and the AFFF firefighting-foam lawsuits cover parallel injury claims, and our explainer on product liability claims covers the failure-to-warn theory that underlies them.

Is a Paraquat Settlement Taxable?

The answer is split, and the distinction matters. Under Internal Revenue Code §104(a)(2), money received as compensation for a physical injury or physical sickness — which is what a Parkinson’s diagnosis represents — is generally not taxable. But other components are treated differently, as the table below summarizes.

Because the taxable pieces — punitive damages and interest — can arrive in the same check as the tax-free compensatory portion, it helps to know which is which before you spend anything. For some claimants, a structured settlement that spreads payments over time can help manage taxes and preserve eligibility for income-based benefits like Medicaid or SSI. None of this is tax advice — the IRS’s Publication 4345 on the taxability of settlements is a useful starting point, but the right move is to review your specific situation with a qualified tax professional.

How Long Until You Get Paid?

There is no single honest date to give, because there isn’t one finalized global settlement — there’s a rolling process. Plaintiffs who have already accepted an individual offer are moving through documentation review and, in some cases, receiving payment now; the court’s March 2026 qualified settlement fund exists specifically to help administer those payouts. Plaintiffs who opted out are on a slower, more uncertain track that now includes meetings with the Special Master, depositions, and — depending on how the courts apply the Durnell ruling — possibly renewed settlement talks or a return toward trial.

In general, once a claim is accepted into a settlement track, documentation is submitted, cases are reviewed and scored, and payments are issued in stages — commonly over several months to a couple of years. Two things commonly slow the amount that lands in your bank account: liens — sums that Medicare, Medicaid, or private insurers may recover for related care — and the time it takes to verify each claim.

How to File a Paraquat Claim

This section is informational, not a solicitation. In broad strokes:

1. Confirm and document the diagnosis. Gather medical records showing a physician’s diagnosis of Parkinson’s disease or parkinsonism, ideally with other causes ruled out (idiopathic Parkinson’s).
2. Reconstruct the exposure history. Collect whatever establishes contact with paraquat — RUP logs, applicator licenses, employment records, farm or supplier records, purchase receipts, or a detailed account of when, where, and how exposure happened. See how to prove exposure above.
3. Mind the deadline. Every claim is governed by a statute of limitations that varies by state, and many states apply a “discovery rule” — the clock often starts when you learned, or reasonably should have learned, of the link between your diagnosis and paraquat, not necessarily the date of exposure itself. Missing the deadline can permanently bar a claim, which is why this is time-sensitive without being a reason to panic.
4. Consult a licensed attorney. A lawyer experienced in toxic-exposure litigation can assess eligibility, explain how the 2026 legal developments affect your specific state and claim theory, and outline your options. These cases are typically handled on contingency, meaning no upfront cost and a fee only if the case recovers money.

Because paraquat is an MDL rather than a class action, joining is not automatic — each claimant files an individual case. To understand how that differs, our guide on how to file a class action lawsuit walks through the contrast.

What to Know Before You Settle

A settlement figure is rarely the amount that reaches your pocket, and clear expectations protect you. A few calm, practical points:

• The headline number is not your net. If you hear “$50,000,” that is the gross. Contingency attorney fees, case costs, and any medical or government liens come out first, so the in-hand amount is lower. Ask your attorney for a written estimate of all three.
• Keep your case off social media. Posting about your diagnosis, exposure, or case can be used against you, so it is best to avoid discussing details publicly while a claim is active.
• Think about how you receive the money. A lump sum and a structured payout can affect your taxes and income-based benefits differently, especially if you rely on Medicaid or SSI. Weigh both before you sign.
• Set aside the taxable portion. Punitive damages and interest are taxable even when the core compensatory award is not — knowing the split in advance avoids a surprise at tax time.
• Understand what opting out really means. Given the June 2026 Durnell ruling, walking away from an accepted offer to chase a bigger number at trial carries more legal uncertainty than it did a year ago. Talk through the trade-offs with your attorney in detail.
• Be skeptical of guarantees. No one can promise a specific amount while opt-out cases and the post-Durnell landscape are still being sorted out. A “guaranteed” payout is a red flag, not a reassurance.

Frequently Asked Questions